#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Short-bowel syndrome Ovarian cancer stage IV Vitamin B12 deficiency Anti-myelin-associated glycoprotein antibodies positive Kearns-Sayre syndrome Cutaneous T-cell lymphoma refractory Myelodysplastic syndrome with excess blasts Soft tissue sarcoma Oesophageal adenocarcinoma stage II Rhabdomyosarcoma Anal squamous cell carcinoma Muscular dystrophy Hypertriglyceridaemia Pustular psoriasis Epilepsy More trials…

    Learn about Rare Diseases

    Retinoblastoma Marginal zone lymphoma – Basic Information Immunodeficiency congenital Mantle cell lymphoma stage III Glomerulonephritis membranoproliferative – Life with Disease Indolent systemic mastocytosis – Life with Disease Idiopathic inflammatory myopathy – Treatment Nodal marginal zone B-cell lymphoma – Life with Disease Hairy cell leukaemia – Treatment Leiomyosarcoma recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Omaveloxolone Citalopram Leriglitazone HAFNIUM OXIDE Isavuconazonium Sulfate Tak-280 Tecovirimat Ro7269162 Motixafortide Paxalisib H2-Receptor Antagonist Tinzaparin Obexelimab Kbp-336 Dactylis Glomerata Bi 3032950 Atrasentan Hydrochloride Tiotropium Bromide Monohydrate Tozorakimab Bt-001 More therapies…

    Learn about Your Condition

    Renal cancer recurrent MELAS syndrome Retinal artery occlusion Exposure via breast milk Habitual abortion Spondylolisthesis Biliary tract disorder Mitochondrial myopathy Hodgkin's disease Cognitive disorder Asthmatic crisis Optic ischaemic neuropathy Hot flush Ewing's sarcoma Cardiac failure chronic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Carboplatin
    • Docetaxel
    • Infliximab
    Austria Belgium Denmark Finland France Germany +7

  • Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal squamous cell carcinoma
    Investigated Drugs:
    • Ifinatamab Deruxtecan
    • Docetaxel
    • Irinotecan Hydrochloride
    Belgium Denmark France Germany Italy The Netherlands +5

  • Study on the Safety and Effectiveness of Volrustomig with FOLFIRI and Bevacizumab for Colorectal Cancer Patients Without Liver Metastases

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Volrustomig
    • Irinotecan Hydrochloride Trihydrate
    • Bevacizumab
    France Germany Italy The Netherlands Spain

  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Adagrasib
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Croatia France Germany +9

  • Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Nvl-655
    • Alectinib Hydrochloride
    Austria Belgium Czechia Denmark France Germany +7

  • Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma
    Investigated Drugs:
    • Levoleucovorin
    • Fluorouracil
    • Gemcitabine
    France

  • Study on Detecting Tumor DNA in Blood for Patients with HR+, HER2 Low Metastatic Breast Cancer Using Trastuzumab Deruxtecan After Standard Therapy

    Recruiting

    2 1 1
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    France

  • Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Dostarlimab
    • Bevacizumab
    • GSK5733584
    Belgium Denmark Finland France Germany Greece +6

  • Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Degarelix
    • Leuprorelin Acetate
    • Relugolix
    Belgium Croatia Czechia Denmark France Ireland +4

  • Study on the Effectiveness and Safety of BAY 2927088 for Patients with Advanced Solid Tumors with HER2 Mutations

    Recruiting

    2 1 1
    Investigated Drugs:
    • 3-(3-CHLORO-2-METHOXYANILINO)-2-{3-[(2S)-1,4-DIOXAN-2-YLMETHOXY]PYRIDIN-4-YL}-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE
    • Bay 2927088
    • SEVABERTINIB
    Denmark France Italy Spain
Previous Page
1 2 3 4 5 6 … 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!